ReviewCurrent diabetes reports2005
PPAR ligands: potential therapies for metabolic syndrome.
Review in Current diabetes reports, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 55 citations in OpenAlex.
- Baicalin alleviates sepsis-associated acute kidney injury through activation of the PPAR-γ/UCP1 signaling pathway.Renal failure · 2025Article
- Article
- The Antagonist Effect of Arachidonic Acid onInternational journal of molecular sciences · 2019Article
- Mouse Cardiac Pde1C Is a Direct Transcriptional Target of Pparα.International journal of molecular sciences · 2018Article
- Enantioselective Synthesis of a Novel Thiazoline Core as a Potent Peroxisome Proliferator-Activated Receptor δ Agonist.ACS omega · 2018Article
- Identification of differentially expressed genes and pathways for intramuscular fat metabolism between breast and thigh tissues of chickens.BMC genomics · 2018Article
- Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation.Cellular and molecular neurobiology · 2018Review
- Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro.Scientific reports · 2017Article
- Investigations on Binding Pattern of Kinase Inhibitors with PPARPPAR research · 2017Article
- SR2067 Reveals a Unique Kinetic and Structural Signature for PPARγ Partial Agonism.ACS chemical biology · 2016Article
- Analysis of RXR/THR and RXR/PPARG2 heterodimerization by bioluminescence resonance energy transfer (BRET).PloS one · 2013Article
- Peroxisome proliferator-activated receptor β/δ cross talks with E2F and attenuates mitosis in HRAS-expressing cells.Molecular and cellular biology · 2012Article
- Peroxisome proliferator-activated receptor β/δ induces myogenesis by modulating myostatin activity.The Journal of biological chemistry · 2012Article
- Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors.The Journal of biological chemistry · 2012Article
- Immunomodulatory action of dietary fish oil and targeted deletion of intestinal epithelial cell PPARδ in inflammation-induced colon carcinogenesis.American journal of physiology. Gastrointestinal and liver physiology · 2012Article
- Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.Future cardiology · 2010Review
- Role of Peroxisome Proliferator-Activated Receptor (PPAR)δ in Embryonic Stem Cell Proliferation.International journal of stem cells · 2009Review
- Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis.Carcinogenesis · 2008Article
- Ligand activation of peroxisome proliferator-activated receptor-beta/delta(PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytes.Cellular signalling · 2007Article
- Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease.Current neuropharmacology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MS), a condition characterized by multiple related clinical disorders including insulin resistance, central obesity, hyperlipidemia, hypertension, and heart disease, is an increasingly prevalent disease in industrialized societies. The intense research interest in the peroxisome proliferator-activated receptors (PPARs), by both the pharmaceutical industry and academia, stems largely from the well-documented therapeutic actions of their synthetic agonists in alleviating several of the maladies associated with MS. This report focuses on the current understanding of the mechanisms of action of PPAR agents and their clinical use in the context of MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.